COVID-19 Supplements: Yale Study Shows Lipidomic Changes That Mark COVID-19 Disease Severity. Resolvins From Omega-3 Fatty Acids Could Help
: A New study by researchers from Yale University show how lipidomic disruption and changes mark the severity of COVID-19 disease especially the start and progression of cytokine storms.
The research finding that is yet to be peer-reviewed is published on a preprint server. https://www.medrxiv.org/content/10.1101/2020.07.09.20149849v1
The research indirectly also implies that resolvins which are a type of immune-modulators derived from Omega-3 Fatty Acids could help prevent cytokine storms. Thailand Medical News had already covered this in a previous article: https://www.thailandmedical.news/news/breaking-covid-19-supplements-us-study-finds-that-resolvins-from-omega-3-fatty-acids-could-prevent-covid-19-cytokine-storms
The COVID-19 pandemic has affected more than 14.5 million people worldwide with mortality exceeding 603,500 patients. Risk factors associated with severe disease and mortality includes advanced age, hypertension, diabetes, and obesity.
To date clear mechanistic understanding of how these comorbidities converge to enable severe infection is lacking. Notably each of these risk factors pathologically disrupts the lipidome and this disruption may be a unifying feature of severe COVID-19.
In the study the researchers attempt to provide the first in depth interrogation of lipidomic changes, including structural-lipids as well as the eicosanoids and docosanoids lipid mediators (LMs), that mark COVID-19 disease severity.
The study findings reveal that the progression from moderate to severe disease is marked by a loss of specific immune regulatory lipid mediators (LMs) and increased pro-inflammatory species. Given the important immune regulatory role of LMs, these data provide mechanistic insight into the immune balance in COVID-19 and potential targets for therapy with currently approved pharmaceuticals and even supplements like Omega-3 fatty acids.
These study findings provide the first detailed lipidomic understanding of COVID-19 disease progression and represent one of the first combinations of bulk lipidomic and eicosanoid data to map mobilization of lipids in human infectious disease. It provides evidence that a systemic lipid network consisting of liberated PUFAs from plasmalogen and their subsequent conversion to LMs, capable of modulating inflammatory responses, characterizes both the onset and severity of COVID-19. Specifically, the loss of the immune regulatory prostaglandins and the increased production of AA-derived products of ALOX5 and cytochrome P450 provides both a measure of disease severity and a mechanistic understanding of the immune balance allowing for patient recovery. Importantly, these pathways are directly targetable with drugs previously approved for use in other inflammatory conditions and, thus, provide therapeutic opportunities to control severe COVID-19.
For more on COVID-19 Supplements
and research, keep on logging to Thailand Medical News.